Ipsen Deal History & Licensing Activity
Ipsen is a large pharma headquartered in France. Over the past three years, Ipsen has been involved in 5 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Ipsen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Ipsen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| navtemadlin | Kartos Therapeutics | Small Molecules | Phase 3 | acquisition | Aug 21, 2026 |
| potravitug | Memo Therapeutics AG | Antibodies | Phase 2 | acquisition | Jul 1, 2026 |
Ipsen Pipeline Focus
Therapeutic areas and modalities where Ipsen is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Ipsen Strategic Signals
Key indicators of Ipsen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Ipsen Clinical Pipeline
Ipsen has 50 active clinical trials across 8 development phases.
19
Unknown
1
Not Applicable
1
Phase 4
1
Phase 1
6
Phase 1/2
8
Phase 2
1
Phase 2/3
13
Phase 3
See How Your Asset Matches Ipsen's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Ipsen Licensing & Deal Activity
Ipsen is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Ipsen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Ipsen include Solid Tumors (14 deals and trials), Gastroenterology (9 deals and trials), CNS Disorders (5 deals and trials), and Hematology (3 deals and trials). In terms of modality, Ipsen has shown particular interest in small molecules, antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ipsen and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Ipsen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.